Rational development of multicomponent mRNA vaccine candidates against mpox.
Emerg Microbes Infect
; 12(1): 2192815, 2023 Dec.
Article
in English
| MEDLINE | ID: covidwho-2288611
ABSTRACT
The re-emerging mpox (formerly monkeypox) virus (MPXV), a member of Orthopoxvirus genus together with variola virus (VARV) and vaccinia virus (VACV), has led to public health emergency of international concern since July 2022. Inspired by the unprecedent success of coronavirus disease 2019 (COVID-19) mRNA vaccines, the development of a safe and effective mRNA vaccine against MPXV is of high priority. Based on our established lipid nanoparticle (LNP)-encapsulated mRNA vaccine platform, we rationally constructed and prepared a panel of multicomponent MPXV vaccine candidates encoding different combinations of viral antigens including M1R, E8L, A29L, A35R, and B6R. In vitro and in vivo characterization demonstrated that two immunizations of all mRNA vaccine candidates elicit a robust antibody response as well as antigen-specific Th1-biased cellular response in mice. Importantly, the penta- and tetra-component vaccine candidates AR-MPXV5 and AR-MPXV4a showed superior capability of inducing neutralizing antibodies as well as of protecting from VACV challenge in mice. Our study provides critical insights to understand the protection mechanism of MPXV infection and direct evidence supporting further clinical development of these multicomponent mRNA vaccine candidates.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Monkeypox
/
COVID-19
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Animals
Language:
English
Journal:
Emerg Microbes Infect
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS